The global cancer vaccines market size is estimated to be growing at a CAGR of 17.28% during the forecast period. As a result, the market size is projected to value USD 11.97 billion by 2027 from USD 5.39 billion in 2022.
Vaccines were mostly used to prevent contagious diseases; they work by improving the immune response against pathogens. Similarly, cancer vaccines work by activating the immune system to attack cancer cells. Researchers developed therapeutic cancer vaccines to alleviate patients suffering from cancer. With the new technological advances, cancer vaccines have been developed as a new therapeutic way for cancer prevention and eradication. Broad ranges of therapeutics are currently available to combat cancer effectively, but they suffer from many glitches like low effectiveness and high specificity.
MARKET DRIVERS:
The factor which is significantly boosting the growth of the global cancer vaccines market is the rise in the prevalence of various cancers across the world.
The influx of novel cancer vaccines into the market contributes to developing the global cancer vaccines market. The increase in demand for preventive vaccines among people due to increased awareness of infectious diseases catalyzes the growth of the cancer vaccines market. Also, governments and private organizations' increased investments for the production of cancer vaccines and the development of alternative therapies due to a consistently rising account of cancer contribute to the growth of the global cancer vaccines market.
Steadily increasing demand and adoption rates of therapeutic and preventive vaccines are expected to create lucrative growth opportunities for key market players in the global cancer vaccines market during the outlook period. Emerging economies of developing nations such as China and India are leading to the expansion and technological advancement of healthcare and are likely to offer many growth opportunities for the stakeholders operating in the worldwide cancer vaccines market. Increased focus of medical professionals on research and development of alternative therapies and treatments owing to the continually growing prevalence of cancer at an exponential rate is likely to provide lucrative growth opportunities for the key players functioning in the cancer vaccines market during the projection period.
MARKET RESTRAINTS:
Stringent regulations and time-taking approval procedures of the FDA, restricting or delaying the launch of newly developed vaccines into the market, are a challenge to the key players and stakeholders, eventually limiting the growth of the cancer vaccines market. Side effects associated with the available therapies are challenging the development of the global cancer vaccine market.
Impact of COVID-19 on the global cancer vaccines market:
COVID-19 was declared an international public health emergency by the World Health Organization (WHO) on January 30, 2020. About 210 countries have been affected by COVID-19. It is a large virus family that causes many illnesses, from the common cold to more serious respiratory illnesses. Some businesses, particularly those with insufficient liquidity, can be stressed by temporary disruptions in inputs or output. Furthermore, delayed shipments and production schedules cause financial difficulties for businesses with high debt levels. Due to shutdowns in various COVID-19-affected countries, the COVID-19 pandemic has slowed cancer vaccine production and the import and export of raw materials and finished products. Cancer (also known as malignant tumor or neoplasms) is a condition in which abnormal cells develop and invade other tissues uncontrolled. This could result in cancer tumors spreading uncontrollably across the body. However, the cancer vaccine market is projected to have a significant growth rate in the coming years.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2021 to 2027 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2027 |
|
Segments Covered |
By Cancer Type, Vaccine Type, End Users, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Dendreon, GlaxoSmithKline, Merck, Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, OncoThyreon, Oncovir, Oxford BioMedica, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen and Vaxon Biotech |
This research report on the global cancer vaccines market has been segmented and sub-segmented based on the cancer type, vaccine type, end-users, and region.
Cancer Vaccines Market - By Cancer Type:
Based on the cancer type, the cervical cancer segment accounted for the largest share of global cancer vaccines market revenue in 2019 and is expected to maintain its dominance over the forecast period, owing to an increase in the number of people infected with the human papillomavirus (HPV). Furthermore, the high prevalence of cervical cancer drives market development. On the other hand, prostate cancer is projected to expand at the fastest rate of 14.10 percent from 2020 to 2025, owing to increased demand for Provenge (prostate cancer vaccine) and an increase in the number of prostate cancer vaccines in development.
Cancer Vaccines Market - By Vaccine Type:
Based on the vaccine type, the global demand for recombinant cancer vaccines dominated in 2019 and is projected to continue to do so over the forecast period. This is since recombinant technology has been used to authorize several cancer vaccines, including Cervarix.
Cancer Vaccines Market - By End User:
Based on end-users, the Cancer Treatment Centers contribute the largest share of revenues to the global cancer vaccines market. They are likely to continue the trend over the estimated period owing to the huge patient pool.
Cancer Vaccines Market - By Region:
Geographically, North America is predicted to account for the largest share in the global cancer vaccines market due to increased cancer deaths. The government's escalating awareness about cancer by the government grows the patient’s treatment. High prevalence of cancer and the region's developed healthcare system, North America is projected to expand. According to the National Cancer Centre, cancers can be avoided using vaccines such as the Human papillomavirus (HPV) vaccine and the Hepatitis B virus vaccine (HBV). This vaccine is now recommended for men who have advanced types of cancer. Also, the FDA approved talimogene laherparepvec (T-VEC, or Imlygic), the first oncolytic virus therapy, in October 2015. This vaccine is used to treat metastatic melanoma that cannot be removed surgically.
The Asia Pacific is expected to show the highest growth due to increased healthcare expenditure in developing countries in this region. Increasing cancer vaccine acceptance, an increase in the number of cancer patients in emerging economies, the growth of the R&D industry, healthcare reforms, and technological advances in cancer vaccines are providing lucrative opportunities for key players operating in the cancer vaccines market in the Asia Pacific. Furthermore, increased investment from both the public and private sectors to develop novel cancer vaccines, increased number of hospitals and diagnostic centers with advanced medical facilities, and a large population base contribute to the market's growth. Besides that, leading manufacturers' increased emphasis on expanding their geographical presence in developing Asia-Pacific countries to capture high market share is expected to fuel the region's cancer vaccines market growth.
KEY MARKET PLAYERS:
Companies that are playing a leading role in the global cancer vaccines market profiled in the report are Dendreon, GlaxoSmithKline, Merck, Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, OncoThyreon, Oncovir, Oxford BioMedica, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen and Vaxon Biotech.
RECENT MARKET HAPPENINGS:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology Data
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment type
5.1.1 Prophylactic
5.1.2 Therapeutic
5.1.3 Y-o-Y Growth Analysis, By Cancer Type
5.1.4 Market Attractiveness Analysis, By Cancer type
5.1.5 Market Share Analysis, By Cancer Type
5.2 Cancer Type
5.2.1 Introduction
5.2.2 Prostate Cancer
5.2.3 Cervical Cancer
5.2.4 Colorectal Cancer
5.2.5 Throat Cancer
5.2.6 Others
5.2.7 Y-o-Y Growth Analysis, By Cancer Type
5.2.8 Market Attractiveness Analysis, By Cancer type
5.2.9 Market Share Analysis, By Cancer Type
5.3 Vaccine Type
5.3.1 Introduction
5.3.2 Tumour cell Vaccines
5.3.3 Protein or Peptide Vaccines
5.3.4 Genetic Vaccines
5.3.5 Dendritic cell Vaccines
5.3.6 other Vaccines
5.3.7 Y-o-Y Growth Analysis, By Vaccine Type
5.3.8 Market Attractiveness Analysis, By Vaccine Type
5.3.9 Market Share Analysis, By Vaccine Type
5.4 End Users
5.4.1 Introduction
5.4.2 Cancer Treatment Centers
5.4.3 Research Institutes
5.4.4 Y-o-Y Growth Analysis, By End User
5.4.5 Market Attractiveness Analysis, By End User
5.4.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.4 Market Attractiveness Analysis
6.1.5 Market Share Analysis
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Merck & co
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Dendreon
8.3 Glaxosmithkline
8.4 AstraZeneca plc
8.5 Aduro BioTech
8.6 MedImmune
8.7 Sanofi
8.8 Galena Biopharma
8.9 Ubivac
8.10 Oxford Biomedica
8.11 Immunofrontier Inc
8.12 Oncovir Inc
8.13 Immune Cell Therapy (ICT)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
